falsefalse

Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice - Episode 3

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

, , ,

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
    EP. 2: The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC
    Now Viewing
    EP. 3: Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials
    EP. 4: Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC
    EP. 5: Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial
    EP. 6: The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC
    EP. 7: Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC
    EP. 8: Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors
    EP. 9: CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
    EP. 10: KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC
    EP. 11: EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC
    EP. 12: POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC
    EP. 13: Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
    EP. 14: The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC
    EP. 15: The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC
    EP. 16: A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations
    EP. 17: The Exciting Future of NSCLC Treatment
    EP. 18: Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
    EP. 19: POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations
    EP. 20: Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
    EP. 21: Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations
    EP. 22: Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

    Related Content:

    Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical PracticeOncLive Peer Exchange® Lung CancerImmunotherapy in Lung Cancer
    Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung
    Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
    Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm
    x